STEPHEN J HOFFMAN
CIK 1190418 · Chief Executive Officer · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$18.1K
Companies
7
Total Filings
42
Lifetime Open-Market Net
$9.40M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TLPH | Director | 13,959 | $1.30 | $18.1K | $0 | 3 | 2026-06-24 |
| TALPHERA, INC. (ACRX) Delisted | Director | 146,015 | $0.86 | $125.6K | $0 | 8 | 2023-12-13 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 312,000 | $38.22 | $11.92M | $3.00M | 9 | 2021-12-29 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | Chief Executive Officer | 131 | $33.00 | $4.3K | $64.1K | 3 | 2019-05-16 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 249,052 | $0.00 | $149 | $8.79M | 4 | 2016-06-07 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Director | 0 | — | — | -$2.45M | 12 | 2012-09-05 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | 1,376,190 | — | — | $0 | 1 | 2007-05-31 |
Recent Filings · Page 3 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-07 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-29 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-03-17 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Buy (P) | +700,000 | $5.78M | EDGAR |
| 2015-03-02 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-03-11 | TALPHERA, INC. (ACRX) Delisted | Other (J) | −1,300,000 | $0 | EDGAR |
| 2014-02-11 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Mixed | +1,292,415 | $3.01M | EDGAR |
| 2014-02-05 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Mixed | +1,734,751 | $3.00M | EDGAR |
| 2013-09-16 | TALPHERA, INC. (ACRX) Delisted | Buy (P) | — | $0 | EDGAR |
| 2012-09-05 | ALLOS THERAPEUTICS INC (ALTH) Delisted | U | −565,671 | -$1.03M | EDGAR |
| 2012-07-26 | TALPHERA, INC. (ACRX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.